These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24435449)

  • 1. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.
    Liu S; Walker SR; Nelson EA; Cerulli R; Xiang M; Toniolo PA; Qi J; Stone RM; Wadleigh M; Bradner JE; Frank DA
    Mol Cancer Ther; 2014 May; 13(5):1194-205. PubMed ID: 24435449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
    Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
    Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.
    Boehm D; Calvanese V; Dar RD; Xing S; Schroeder S; Martins L; Aull K; Li PC; Planelles V; Bradner JE; Zhou MM; Siliciano RF; Weinberger L; Verdin E; Ott M
    Cell Cycle; 2013 Feb; 12(3):452-62. PubMed ID: 23255218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
    Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
    Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JQ1 affects BRD2-dependent and independent transcription regulation without disrupting H4-hyperacetylated chromatin states.
    Handoko L; Kaczkowski B; Hon CC; Lizio M; Wakamori M; Matsuda T; Ito T; Jeyamohan P; Sato Y; Sakamoto K; Yokoyama S; Kimura H; Minoda A; Umehara T
    Epigenetics; 2018; 13(4):410-431. PubMed ID: 30080437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
    Ott CJ; Kopp N; Bird L; Paranal RM; Qi J; Bowman T; Rodig SJ; Kung AL; Bradner JE; Weinstock DM
    Blood; 2012 Oct; 120(14):2843-52. PubMed ID: 22904298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses.
    Belkina AC; Nikolajczyk BS; Denis GV
    J Immunol; 2013 Apr; 190(7):3670-8. PubMed ID: 23420887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation.
    Toniolo PA; Liu S; Yeh JE; Moraes-Vieira PM; Walker SR; Vafaizadeh V; Barbuto JA; Frank DA
    J Immunol; 2015 Apr; 194(7):3180-90. PubMed ID: 25725100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromodomain and Extraterminal Inhibition by JQ1 Produces Divergent Transcriptional Regulation of Suppressors of Cytokine Signaling Genes in Adipocytes.
    Mota de Sá P; Richard AJ; Stephens JM
    Endocrinology; 2020 Feb; 161(2):. PubMed ID: 31875887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
    Ceribelli M; Kelly PN; Shaffer AL; Wright GW; Xiao W; Yang Y; Mathews Griner LA; Guha R; Shinn P; Keller JM; Liu D; Patel PR; Ferrer M; Joshi S; Nerle S; Sandy P; Normant E; Thomas CJ; Staudt LM
    Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11365-70. PubMed ID: 25049379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal transducer and activator of transcription STAT5 is recruited to c-Myc super-enhancer.
    Pinz S; Unser S; Rascle A
    BMC Mol Biol; 2016 Apr; 17():10. PubMed ID: 27074708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function.
    Pinz S; Unser S; Buob D; Fischer P; Jobst B; Rascle A
    Nucleic Acids Res; 2015 Apr; 43(7):3524-45. PubMed ID: 25769527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
    Stewart HJ; Horne GA; Bastow S; Chevassut TJ
    Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
    Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
    Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The suppression of bromodomain and extra-terminal domain inhibits vascular inflammation by blocking NF-κB and MAPK activation.
    Huang M; Zeng S; Zou Y; Shi M; Qiu Q; Xiao Y; Chen G; Yang X; Liang L; Xu H
    Br J Pharmacol; 2017 Jan; 174(1):101-115. PubMed ID: 27774624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NF-κB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells.
    Hishiki K; Akiyama M; Kanegae Y; Ozaki K; Ohta M; Tsuchitani E; Kaito K; Yamada H
    Leuk Res; 2018 Nov; 74():57-63. PubMed ID: 30300821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.
    Kamijo H; Sugaya M; Takahashi N; Oka T; Miyagaki T; Asano Y; Sato S
    Arch Dermatol Res; 2017 Aug; 309(6):491-497. PubMed ID: 28593508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.
    Lambert JP; Picaud S; Fujisawa T; Hou H; Savitsky P; Uusküla-Reimand L; Gupta GD; Abdouni H; Lin ZY; Tucholska M; Knight JDR; Gonzalez-Badillo B; St-Denis N; Newman JA; Stucki M; Pelletier L; Bandeira N; Wilson MD; Filippakopoulos P; Gingras AC
    Mol Cell; 2019 Feb; 73(3):621-638.e17. PubMed ID: 30554943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.